Know What's Happening in Pharma

What's happening: Cell‑free PL‑display platform accelerates peptide screening ten‑fold

Researchers at the Innovation Center of NanoMedicine introduced PL‑display, a cell‑free system that immobilizes individual peptides on magnetic beads for rapid screening. The platform achieves more than ten‑fold efficiency gains over traditional cell‑based displays and remains functional under high‑temperature, high‑salt, or toxic‑protein conditions.

Also developing:

• •Roche reports positive Phase III results for fenebrutinib in relapsing and primary progressive multiple sclerosis
• •Takeda and Protagonist receive FDA acceptance and priority review for Rusfertide for polycythemia vera
• •Sanofi’s rilzabrutinib granted orphan drug designation in Japan for IgG4‑related disease
• •Lynk Pharmaceuticals announces positive Phase III topline data for zemprocitinib in moderate‑to‑severe atopic dermatitis